DOI: 10.1039/d6ra08049a ISSN: 2046-2069
Design, synthesis, and evaluation of novel hydrazide and hydroxamate derivatives as potent antileukemic agents with preferential HDAC-2 inhibitory activity over class I isoform
Fatma Elzahraa Ali, Abdullah Yahya Abdullah Alzahrani, Bandar A. Alyami, Stefan Bräse, Anber F. Mohammed, Bahaa G. M. YoussifDeveloping isoform-selective HDAC inhibitors is a promising cancer therapy, maximizing efficacy while minimizing side effects of pan-HDAC inhibition.